Diabetic RetinopathyRETINOMEDNCT07828821
Screening for Diabetic RETINopathy Using a Non-mydriatic Retinograph Funduscope in Occupational MEDicine
A study testing Non-mydriatic retinography and Self-administered questionnaire in people with Diabetic Retinopathy, run by University Hospital, Clermont-Ferrand at 1 site in France.
Trial summary
Diabetic retinopathy is a complication of diabetes that can affect vision. Early detection and appropriate management can help prevent or delay vision loss. However, some people with diabetes do not receive the recommended regular eye examinations. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Diabetic Retinopathy
- What is being tested?
- Non-mydriatic retinography and Self-administered questionnaire
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 400 participants
- Where
- 1 siteFrance
- Study dates
- Oct 2026to Jun 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Worker
- Adult (≥18 years old)
- Diabetic
- Affiliated with a Social Security scheme
- Able to give informed consent to participate in the research
Who cannot join
- Protected persons (minors, guardianship, curatorship, deprived of freedoms, safeguard of justice)
- Pregnant or breastfeeding women; these women may be offered participation after pregnancy and/or breastfeeding
- Non-voluntary person
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site
CHU de Clermont-Ferrand
Clermont-Ferrand
Lise Laclautre, 0473754963, promo_interne_drci@chu-clermontferrand.fr
Frédéric Dutheil
About this study
Diabetic retinopathy is a complication of diabetes that can affect vision. Early detection and appropriate management can help prevent or delay vision loss. However, some people with diabetes do not receive the recommended regular eye examinations.
The RETINOMED study is a pilot study designed to evaluate the feasibility of offering diabetic retinopathy screening to workers with diabetes through an Occupational Health service.
Read more
Participants will attend a single study visit at the Occupational Health Department of Clermont-Ferrand University Hospital. During this visit, retinal photographs will be taken using a non-mydriatic retinal camera, which does not require pupil dilation. Participants will also complete a questionnaire about their sociodemographic and occupational characteristics, lifestyle, and diabetes.
The study will assess the acceptability of this screening program among eligible workers. It will also estimate the prevalence of diabetic retinopathy among screened workers and explore participant characteristics that may be associated with diabetic retinopathy.
Read the detailed description
RETINOMED is a monocentric, pilot exploratory study conducted at the Occupational Health Department of Clermont-Ferrand University Hospital, France. The study primarily aims to assess the feasibility of implementing diabetic retinopathy screening in an Occupational Health setting.
Occupational Health services provide regular access to a large working population and may therefore offer an opportunity to improve access to diabetic retinopathy screening. Integrating such screening into Occupational Health could contribute to earlier detection of diabetic retinopathy and facilitate referral to appropriate ophthalmologic care when needed.
Workers with diabetes may be informed about the study during an Occupational Health visit or through a screening campaign conducted by the Occupational Health Department. Workers who wish to participate will receive information about the study and will attend a single inclusion and screening visit.
After informed consent, participants will undergo retinal photography using the FundusScope FC161 non-mydriatic retinal camera. The examination is non-invasive and does not require pupil dilation. Retinal images will subsequently be assessed by the Ophthalmology Department of Clermont-Ferrand University Hospital.
Participants will also complete a self-administered questionnaire, electronically using REDCap or on paper when necessary. The questionnaire will collect information on diabetes, sociodemographic and occupational characteristics, lifestyle factors, and several self-reported measures related to health and work.
Each participant will attend only one study visit, lasting approximately 30 minutes. Participants will be informed of their retinal screening results and, when necessary, will be referred to an appropriate care pathway.
The primary focus of the study is the acceptability of diabetic retinopathy screening in the Occupational Health setting. The study will also estimate the prevalence of diabetic retinopathy detected through the screening program and describe the characteristics of participating workers, including factors potentially associated with diabetic retinopathy.
- Conditions
- Diabetic Retinopathy
- Being tested
- Non-mydriatic retinography, Self-administered questionnaire
- Keywords
- Diabetic retinopathy, Diabetes, Occupational Health, Screening, Retinophotography
- Medical subject headings
- Diabetic Retinopathy, Diabetes Mellitus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Non-mydriatic retinographyDevice
Retinophotography will be performed using the non-mydriatic retinograph FundusScope FC161. The retinal images will subsequently be analyzed by the Ophthalmology Department. Screened workers will be informed of their results and will be redirected to the care pathway if necessary.
Self-administered questionnaireOther
Participants will complete a self-administered questionnaire, administered online via REDCap® or in paper version for individuals who may have difficulty using computers.
The questionnaire will collect information about diabetes, occupational characteristics, sociodemographic characteristics, visual analog scales of stress at work, stress at home, anxiety, sleep quality, fatigue, mood/morale, burnout, autonomy at work, workload, support from the hierarchy, support from colleagues and satisfaction at work in relation to efforts deployed, and lifestyle variables including sitting, physical activity, alcohol and tobacco.
| Study group | Role | What they receive |
|---|---|---|
| Diabetic retinopathy screening | Experimental | Participants will undergo retinophotography in the Occupational Health Department using the non-mydriatic retinograph FundusScope FC161. Participants will also complete a self-administered questionnaire, administered online via REDCap® or in paper version for individuals who may have difficulty using computers. Receives: Device: Non-mydriatic retinography; Other: Self-administered questionnaire |
What is being measured
The primary outcome is the main question the study is designed to answer.
Acceptability of diabetic retinopathy screening in an Occupational Health setting
Proportion of eligible workers who consent to undergo the proposed retinal screening during their Occupational Health visit.
Measured: Day 1
Secondary outcomes (44)
Prevalence of diabetic retinopathy detected by retinophotography in diabetic workers
Proportion of screened diabetic workers with diabetic retinopathy detected by retinophotography.
Measured: Day 1
Type of diabetes
Type of diabetes (type 1, type 2, or other), assessed using the self-administered questionnaire. Results will be reported as the percentage of participants in each category.
Measured: Day 1
Year of diabetes diagnosis
Year of discovery of diabetes, assessed using the self-administered questionnaire. The measurement unit is calendar year.
Measured: Day 1
Last HbA1c value
Last HbA1c value, assessed using the self-administered questionnaire. HbA1c is reported as a percentage (%).
Measured: Day 1
Time since last HbA1c measurement
Time since the last HbA1c measurement assessed using the self-administered questionnaire. Categories are 1 month, 2 months, 3 months, 4 to 6 months, more than 6 months, and more than 1 year. Results will be reported as the percentage (%) of participants in each category.
Measured: Day 1
Diabetes complications
Presence of diabetes complications, assessed using the self-administered questionnaire. Diabetes complications are reported by participants in a free-text field.
Measured: Day 1
Time since last ophthalmological assessment
Time since the participant's last ophthalmological assessment, assessed using the self-administered questionnaire and expressed in months.
Measured: Day 1
Time since last cardiovascular assessment
Time since the participant's last cardiovascular assessment, assessed using the self-administered questionnaire and expressed in months.
Measured: Day 1
Antidiabetic treatment
Antidiabetic treatment assessed using the self-administered questionnaire. Categories include insulin, oral antidiabetic treatment, physical activity, diet, and other treatment. Multiple responses are possible. Results will be reported as the percentage (%) of participants reporting each category.
Measured: Day 1
Age
Age assessed using the self-administered questionnaire and expressed in years.
Measured: Day 1
Gender
Grnder assessed using the self-administered questionnaire. Categories are female and male. Results will be reported as the percentage (%) of participants in each category.
Measured: Day 1
Body mass index
Body mass index calculated from self-reported height in centimeters and weight in kilograms collected using the questionnaire. Body mass index is expressed in kg/m².
Measured: Day 1
Family status
Family status assessed using the self-administered questionnaire. Categories are living as a couple and single. Results will be reported as the percentage (%) of participants in each category.
Measured: Day 1
Number of children
Number of children assessed using the self-administered questionnaire. Categories are none, 1, 2, and 3 or more children. Results will be reported as the percentage (%) of participants in each category.
Measured: Day 1
Educational level
Educational level assessed using the self-administered questionnaire. Categories are " ≤ brevet des collèges , CAP/BEP , Bac , Bac+1/+4 , Bac+5 and >Bac+5" Results will be reported as the percentage (%) of participants in each category.
Measured: Day 1
Daily tobacco consumption
Number of cigarettes smoked per day assessed using the self-administered questionnaire. Categories are 0, 1-4, 5-9, 10-14, 15-19, and >20 cigarettes per day. Results will be reported as the percentage (%) of participants in each category.
Measured: Day 1
Weekly alcohol consumption
Number of alcoholic drinks consumed per week assessed using the self-administered questionnaire. Categories are 0, 1-4, 5-9, 10-14, 15-19, and >20 drinks per week. Results will be reported as the percentage (%) of participants in each category.
Measured: Day 1
Leisure-time physical activity
Duration of leisure-time physical activity assessed using the self-administered questionnaire and expressed in hours per week.
Measured: Day 1
Occupational physical activity
Duration of physical activity at work assessed using the self-administered questionnaire and expressed in hours per week.
Measured: Day 1
Total daily sitting time
Total sitting time assessed using the self-administered questionnaire and expressed in hours per day.
Measured: Day 1
Daily sitting time at work
Sitting time at work assessed using the self-administered questionnaire and expressed in hours per day.
Measured: Day 1
Occupational status
Current or last occupational status assessed using the self-administered questionnaire. Results will be reported as the percentage (%) of participants in each occupational category.
Measured: Day 1
Sector of activity
Current or last sector of activity assessed using the self-administered questionnaire. Results will be reported as the percentage (%) of participants in each sector of activity.
Measured: Day 1
Weekly working time
Number of hours worked per week assessed using the self-administered questionnaire and expressed in hours per week.
Measured: Day 1
Daily working time
Number of hours worked per working day assessed using the self-administered questionnaire and expressed in hours per working day.
Measured: Day 1
Percentage of working time spent sitting
Proportion of working time spent sitting assessed using the self-administered questionnaire and expressed as a percentage (%).
Measured: Day 1
Night work
Night work assessed using the self-administered questionnaire. Categories are no night work, fixed night work, shift work, variable or occasional night work, and other. Results will be reported as the percentage (%) of participants in each category.
Measured: Day 1
Number of weekends worked per month
Number of weekends worked per month assessed using the self-administered questionnaire. Categories are 0, 1, 2, 3, and 4 or more weekends per month. Results will be reported as the percentage (%) of participants in each category.
Measured: Day 1
Telework
Telework assessed using the self-administered questionnaire as yes or no. Results will be reported as the percentage (%) of participants reporting telework.
Measured: Day 1
Percentage of working time performed as telework
Percentage of working time performed as telework among participants reporting telework, assessed using the self-administered questionnaire. Categories are <20%, 21-40%, 41-60%, 61-80%, and >80%.
Measured: Day 1
Job seniority
Seniority in the current position assessed using the self-administered questionnaire. Categories are <6 months, 6 months to 1 year, 1-3 years, 3-5 years, 5-10 years, and >10 years. Results will be reported as the percentage (%) of participants in each category.
Measured: Day 1
Employment contract
Employment contract assessed using the self-administered questionnaire. Categories are fixed-term contract, permanent contract or tenured position, work-study contract, temporary employment, and other. Results will be reported as the percentage (%) of participants in each category.
Measured: Day 1
Work-related stress assessed using a Visual Analog Scale
Work-related stress assessed using a Visual Analog Scale (VAS) ranging from 0 (minimum) to 100 (maximum).
Measured: Day 1
Home-related stress assessed using a Visual Analog Scale
Home-related stress assessed using a Visual Analog Scale (VAS) ranging from 0 (minimum) to 100 (maximum)
Measured: Day 1
Fatigue assessed using a Visual Analog Scale
Fatigue assessed using a Visual Analog Scale (VAS) ranging from 0 (minimum) to 100 (maximum).
Measured: Day 1
Sleep quality assessed using a Visual Analog Scale
Sleep quality assessed using a Visual Analog Scale (VAS) ranging from 0 (poor) to 100 (excellent).
Measured: Day 1
Anxiety assessed using a Visual Analog Scale
Anxiety assessed using a Visual Analog Scale (VAS) ranging from 0 (minimum) to 100 (maximum).
Measured: Day 1
Mood assessed using a Visual Analog Scale
Mood assessed using a Visual Analog Scale (VAS) ranging from 0 (poor) to 100 (excellent).
Measured: Day 1
Burnout assessed using a Visual Analog Scale
Burnout assessed using a Visual Analog Scale (VAS) ranging from 0 (minimum) to 100 (maximum).
Measured: Day 1
Job control assessed using a Visual Analog Scale
Job control assessed using a Visual Analog Scale (VAS) ranging from 0 (minimum) to 100 (maximum).
Measured: Day 1
Job demand assessed using a Visual Analog Scale
Job demand assessed using a Visual Analog Scale (VAS) ranging from 0 (minimum) to 100 (maximum).
Measured: Day 1
Support from hierarchy assessed using a Visual Analog Scale
Support from hierarchy assessed using a Visual Analog Scale (VAS) ranging from 0 (minimum) to 100 (maximum).
Measured: Day 1
Support from colleagues assessed using a Visual Analog Scale
Support from colleagues assessed using a Visual Analog Scale (VAS) ranging from 0 (minimum) to 100 (maximum).
Measured: Day 1
Job satisfaction in relation to efforts assessed using a Visual Analog Scale
Job satisfaction in relation to efforts made at work assessed using a Visual Analog Scale (VAS) ranging from 0 (minimum) to 100 (maximum).
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Sep 2026
- Study startOct 2026 (estimated)
- Primary completionJun 2029 (estimated)
- Study completionJun 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetic RetinopathyStudies of the same condition, open and under way.
- More trials run by University Hospital, Clermont-FerrandThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Clermont-Ferrand
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Frédéric Dutheil, Principal investigator, University Hospital, Clermont-Ferrand
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07828821
- Sponsor's protocol ID
- RBHP 2025 DUTHEIL (RETINOMED)
- Other IDs
- 2025-A02931-48
- Acronym
- RETINOMED
- Status last verified
- Sep 2026
- First submitted
- 8 Sep 2026
- Last updated
- 18 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Screening for Diabetic RETINopathy Using a Non-mydriatic Retinograph Funduscope in Occupational MEDicine
- ClinicalTrials.gov ID
- NCT07828821
- Acronym / sponsor ID
- RETINOMED / RBHP 2025 DUTHEIL (RETINOMED)
- Conditions
- Diabetic Retinopathy
- Keywords
- Diabetic retinopathy, Diabetes, Occupational Health, Screening, Retinophotography
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- University Hospital, Clermont-FerrandUniversity, hospital or other
- Study start
- Oct 2026 (estimated)
- Primary completion
- Jun 2029 (estimated)
- Study completion
- Jun 2029 (estimated)
- First posted
- 18 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Diabetic retinopathy is a complication of diabetes that can affect vision. Early detection and appropriate management can help prevent or delay vision loss. However, some people with diabetes do not receive the recommended regular eye examinations.
The RETINOMED study is a pilot study designed to evaluate the feasibility of offering diabetic retinopathy screening to workers with diabetes through an Occupational Health service.
Participants will attend a single study visit at the Occupational Health Department of Clermont-Ferrand University Hospital. During this visit, retinal photographs will be taken using a non-mydriatic retinal camera, which does not require pupil dilation. Participants will also complete a questionnaire about their sociodemographic and occupational characteristics, lifestyle, and diabetes.
The study will assess the acceptability of this screening program among eligible workers. It will also estimate the prevalence of diabetic retinopathy among screened workers and explore participant characteristics that may be associated with diabetic retinopathy.
Detailed description
RETINOMED is a monocentric, pilot exploratory study conducted at the Occupational Health Department of Clermont-Ferrand University Hospital, France. The study primarily aims to assess the feasibility of implementing diabetic retinopathy screening in an Occupational Health setting.
Occupational Health services provide regular access to a large working population and may therefore offer an opportunity to improve access to diabetic retinopathy screening. Integrating such screening into Occupational Health could contribute to earlier detection of diabetic retinopathy and facilitate referral to appropriate ophthalmologic care when needed.
Workers with diabetes may be informed about the study during an Occupational Health visit or through a screening campaign conducted by the Occupational Health Department. Workers who wish to participate will receive information about the study and will attend a single inclusion and screening visit.
After informed consent, participants will undergo retinal photography using the FundusScope FC161 non-mydriatic retinal camera. The examination is non-invasive and does not require pupil dilation. Retinal images will subsequently be assessed by the Ophthalmology Department of Clermont-Ferrand University Hospital.
Participants will also complete a self-administered questionnaire, electronically using REDCap or on paper when necessary. The questionnaire will collect information on diabetes, sociodemographic and occupational characteristics, lifestyle factors, and several self-reported measures related to health and work.
Each participant will attend only one study visit, lasting approximately 30 minutes. Participants will be informed of their retinal screening results and, when necessary, will be referred to an appropriate care pathway.
The primary focus of the study is the acceptability of diabetic retinopathy screening in the Occupational Health setting. The study will also estimate the prevalence of diabetic retinopathy detected through the screening program and describe the characteristics of participating workers, including factors potentially associated with diabetic retinopathy.
Study design
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Diabetic retinopathy screening | Experimental | Device: Non-mydriatic retinography, Other: Self-administered questionnaireParticipants will undergo retinophotography in the Occupational Health Department using the non-mydriatic retinograph FundusScope FC161. Participants will also complete a self-administered questionnaire, administered online via REDCap® or in paper version for individuals who may have difficulty using computers. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Worker
- Adult (≥18 years old)
- Diabetic
- Affiliated with a Social Security scheme
- Able to give informed consent to participate in the research
Key exclusion criteria (3 listed)
- Protected persons (minors, guardianship, curatorship, deprived of freedoms, safeguard of justice)
- Pregnant or breastfeeding women; these women may be offered participation after pregnancy and/or breastfeeding
- Non-voluntary person
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Non-mydriatic retinographyRetinophotography will be performed using the non-mydriatic retinograph FundusScope FC161. The retinal images will subsequently be analyzed by the Ophthalmology Department. Screened workers will be informed of their results and will be redirected to the care pathway if necessary. | Device | Diabetic retinopathy screening |
| Self-administered questionnaireParticipants will complete a self-administered questionnaire, administered online via REDCap® or in paper version for individuals who may have difficulty using computers. The questionnaire will collect information about diabetes, occupational characteristics, sociodemographic characteristics, visual analog scales of stress at work, stress at home, anxiety, sleep quality, fatigue, mood/morale, burnout, autonomy at work, workload, support from the hierarchy, support from colleagues and satisfaction at work in relation to efforts deployed, and lifestyle variables including sitting, physical activity, alcohol and tobacco. | Other | Diabetic retinopathy screening |
Primary outcome
Acceptability of diabetic retinopathy screening in an Occupational Health setting
Time frame: Day 1
Proportion of eligible workers who consent to undergo the proposed retinal screening during their Occupational Health visit.
44 secondary outcomes
Prevalence of diabetic retinopathy detected by retinophotography in diabetic workers
Time frame: Day 1
Type of diabetes
Time frame: Day 1
Year of diabetes diagnosis
Time frame: Day 1
Last HbA1c value
Time frame: Day 1
Time since last HbA1c measurement
Time frame: Day 1
Diabetes complications
Time frame: Day 1
Time since last ophthalmological assessment
Time frame: Day 1
Time since last cardiovascular assessment
Time frame: Day 1
Antidiabetic treatment
Time frame: Day 1
Age
Time frame: Day 1
Gender
Time frame: Day 1
Body mass index
Time frame: Day 1
Family status
Time frame: Day 1
Number of children
Time frame: Day 1
Educational level
Time frame: Day 1
Daily tobacco consumption
Time frame: Day 1
Weekly alcohol consumption
Time frame: Day 1
Leisure-time physical activity
Time frame: Day 1
Occupational physical activity
Time frame: Day 1
Total daily sitting time
Time frame: Day 1
Daily sitting time at work
Time frame: Day 1
Occupational status
Time frame: Day 1
Sector of activity
Time frame: Day 1
Weekly working time
Time frame: Day 1
Daily working time
Time frame: Day 1
Percentage of working time spent sitting
Time frame: Day 1
Night work
Time frame: Day 1
Number of weekends worked per month
Time frame: Day 1
Telework
Time frame: Day 1
Percentage of working time performed as telework
Time frame: Day 1
Job seniority
Time frame: Day 1
Employment contract
Time frame: Day 1
Work-related stress assessed using a Visual Analog Scale
Time frame: Day 1
Home-related stress assessed using a Visual Analog Scale
Time frame: Day 1
Fatigue assessed using a Visual Analog Scale
Time frame: Day 1
Sleep quality assessed using a Visual Analog Scale
Time frame: Day 1
Anxiety assessed using a Visual Analog Scale
Time frame: Day 1
Mood assessed using a Visual Analog Scale
Time frame: Day 1
Burnout assessed using a Visual Analog Scale
Time frame: Day 1
Job control assessed using a Visual Analog Scale
Time frame: Day 1
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Diabetic Retinopathy
Recruiting
Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers
Glaucoma, Ocular Hypertension
Active, not recruitingObservational study
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
Active, not recruitingPhase 2
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy
Diabetic Retinopathy, DR
Recruiting
To Investigate the Feasibility and Acceptability of Trained Non-medical Professionals Performing Laser Treatment for Proliferative Diabetic Retinopathy (PDR), and the Potential Impact on Service Capacity. Assess Feasibility of Conducting a Full Trial Comparing Trained ECPs With Ophthalmologists
Proliferative Diabetic Retinopathy (PDR)
RecruitingPhase 2
Oral N-Acetylcysteine on Diabetic Macular Edema
Diabetic Macular Edema (DME)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Frédéric Dutheil principal investigator
University Hospital, Clermont-Ferrand
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Non-mydriatic retinography and Self-administered questionnaire in people with Diabetic Retinopathy, run by University Hospital, Clermont-Ferrand at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 18 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lise Laclautre (0473754963, promo_interne_drci@chu-clermontferrand.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Acceptability of diabetic retinopathy screening in an Occupational Health setting (time frame: Day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2026.